Orphazyme to get rid of two thirds of employees

The recent FDA rejection of Orphazyme's main candidate is now being felt by its employees.

Photo: Nikolaj Skydsgaard/REUTERS / X07081

Biotech firm Orphazyme reports that it has to cut two thirds of its workforce and bid three of its board members farewell.

This is because the US Food and Drug Administration (FDA) rejected the company's main drug candidate for treating Niemann-Pick type C (NPC) earlier in June.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs